<i>BRAF</i> -V600E papillary thyroid cancer: Updated analysis of real-world patient data.
Martina Chirra(University of Cincinnati), Trisha M. Wise‐Draper(University of Cincinnati), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Andrew Elliott(Caris Life Sciences (United States)), Dan P. Zandberg(University of Pittsburgh Medical Center), Jennifer L. Leddon(University of Cincinnati), Farah Abdulla(Caris Life Sciences (United States)), Hira Shaikh(University of Iowa Hospitals and Clinics), Julie McGrath(Caris Life Sciences (United States)), Jennifer M. Johnson(Thomas Jefferson University), Chukwuemeka Ikpeazu(Sylvester Comprehensive Cancer Center), Lova Sun(University of Pennsylvania), Dalia El‐Gamal(University of Nebraska Medical Center), Anthony N. Karnezis(University of California Davis Medical Center)
Cited by 1
Related Papers
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
|Nature Medicine|2021|521
Mre11 Nuclease Activity Has Essential Roles in DNA Repair and Genomic Stability Distinct from ATM Activation
|Cell|2008|341